Most Read Articles
Pearl Toh, 07 Aug 2018
A home-based, self-applied wearable electrocardiogram (ECG) patch facilitates diagnosis of atrial fibrillation (AF) among high-risk individuals, according to the mSToPS* trial.
Roshini Claire Anthony, 3 days ago

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

6 days ago

Fungal microbiome, also called the mycobiome, appears to be highly variable in patients with well-characterized fungal diseases, a recent study has shown. Moreover, severe asthmatics have the highest fungal loads, along with those receiving steroid and antifungal therapy.

Tristan Manalac, 4 days ago
The risk of complicated appendicitis is lower in children with IgE-mediated allergy, according to a recent study.

Direct-acting antivirals do not raise HCC risk in hepatitis C patients

22 Jul 2018
Authorities in Malaysia have approved a compulsory license for Hepatitis C treatment, which allows for cheaper generic medication to be produced without the drug patent holder’s consent.

In patients with advanced hepatitis C infections, taking direct-acting antivirals (DAAs) does not increase the risk of subsequent hepatocellular carcinoma (HCC), a recent study has shown.

Researchers conducted a prospective study of 3,917 patients with hepatitis C infection who were taking DAAs (mean age 58.1±11.9 years; 62.2 percent male); only those with fibrosis stage F3 were eligible for inclusion. Cox regression analyses were performed to identify risk factors for HCC development.

Over a mean follow-up of 536.2±197.6 days, 55 new cases of HCC were reported, yielding an overall incidence rate of 0.97 percent patients per year. The corresponding incidence rate in cirrhotic patients was 1.18 percent patients per year.

Multivariate analysis of baseline variables showed that coinfection with hepatitis B virus (hazard ratio [HR], 3.99; 95 percent CI, 1.24–12.91; p=0.021) and APRI (aspartate aminotransferase-to-platelet ratio) score >2.5 (HR, 2.03; 1.14–3.61; p=0.016) were significant and independent risk factors for HCC development.

In 55 patients who developed HCC (mean age 59.15±9.7 years; 37 males), all hepatitis C virus genotypes were present. The time from DAA initiation to HCC diagnosis ranged from 4–57 weeks and averaged 31.8±20.1 weeks. Twenty-two patients developed HCC while on DAA medication.

In relation to virological outcomes, those who experienced sustained virological response (SVR) were less likely to contract the aggressive form of HCC than in those without SVR (54.6 percent vs 12.1 percent). Moreover, the aggressive HCC pattern was more common during the early periods of observation, while the less aggressive form predominated during later follow-ups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 07 Aug 2018
A home-based, self-applied wearable electrocardiogram (ECG) patch facilitates diagnosis of atrial fibrillation (AF) among high-risk individuals, according to the mSToPS* trial.
Roshini Claire Anthony, 3 days ago

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

6 days ago

Fungal microbiome, also called the mycobiome, appears to be highly variable in patients with well-characterized fungal diseases, a recent study has shown. Moreover, severe asthmatics have the highest fungal loads, along with those receiving steroid and antifungal therapy.

Tristan Manalac, 4 days ago
The risk of complicated appendicitis is lower in children with IgE-mediated allergy, according to a recent study.